key: cord-0316550-fq6im8wf
authors: Berg, Alexander; Clary, James; Hanna, Debra; Nuermberger, Eric; Lenaerts, Anne; Ammerman, Nicole; Ramey, Michelle; Hartley, Dan; Hermann, David
title: Model-Based Meta-Analysis of Relapsing Mouse Model Studies from the Critical Path to Tuberculosis Drug Regimens Initiative Database
date: 2021-09-15
journal: bioRxiv
DOI: 10.1101/2021.09.13.460195
sha: 8f6eba06f3b22789d2932dbe66c2af53905d1b7a
doc_id: 316550
cord_uid: fq6im8wf

Tuberculosis (TB), the disease caused by Mycobacterium tuberculosis (Mtb), remains a leading infectious disease-related cause of death worldwide, necessitating the development of new and improved treatment regimens. Non-clinical evaluation of candidate drug combinations via the relapsing mouse model (RMM) is an important step in regimen development, through which candidate regimens that provide the greatest decrease in probability of relapse following treatment in mice may be identified for further development. Although RMM studies are a critical tool to evaluate regimen efficacy, making comprehensive “apples to apples” comparisons of regimen performance in the RMM has been a challenge, in large part due to the need to evaluate and adjust for variability across studies arising from differences in design and execution. To address this knowledge gap, we performed a model-based meta-analysis on data for 17 unique regimens obtained from a total of 1592 mice across 28 RMM studies. Specifically, a mixed-effects logistic regression model was developed that described the treatment duration-dependent probability of relapse for each regimen and identified relevant covariates contributing to inter-study variability. Using the model, covariate-normalized metrics of interest, namely treatment duration required to reach 50% and 10% relapse probability, were derived and used to compare relative regimen performance. Overall, the model-based meta-analysis approach presented herein enables cross-study comparison of efficacy in the RMM, and provides a framework whereby data from emerging studies may be analyzed in the context of historical data to aid in selecting candidate drug combinations for clinical evaluation as TB drug regimens.

Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), infects an 45 estimated one quarter of the world's population, and causes an estimated 1.4 million TB-related 46 deaths per year, making it the leading worldwide cause of death due to a single infectious disease 47 excluding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1) (2) (3) . Despite a few 48 successes in the past decade in bringing forward new treatments for drug-resistant pulmonary TB 49 (4-6), progress in advancing new drugs and regimens for pulmonary TB has been limited. The 50 standard of care treatment regimen for drug-susceptible pulmonary TB, based on the combination 51 of isoniazid, rifampin, pyrazinamide, and ethambutol, remains essentially unchanged for more than 52 30 years (7). While the regimen is efficacious (~90% cure rates in a clinical trial setting), its 53 complexity, long treatment duration, often poor tolerability, and requirement for high adherence 54 to minimize treatment failure represent gaps that must be addressed through the development of 55 novel treatment regimens. Treatment with the standard regimen is typically six to nine months. 56 The major aim of ongoing TB drug research is to develop markedly shorter treatments (e.g., less 57 than two months) to improve adherence and overall cure rates. Although RMM studies are a critical tool in comparing regimen performance, the model has 89 limitations with regard to study duration, design heterogeneity, and overall utility for decision-90 making. Designs can vary widely from lab to lab, with differences across multiple design elements 91 such as mouse strain, bacterial strain, inoculation dose and route, recovery duration and bacterial 92 culture methods. These inter-study differences, not to mention regimen-specific differences in 93 treatment duration and dose selection, contribute to the observation that the efficacy of a specific 94 regimen in the RMM can vary widely from study to study, even within the same lab, confounding 95 decision-making (11-13). This inter-study variability obviates the comparison of regimens across 96 studies, which is a key limitation when attempting to prioritize regimens as logistical 97 considerations typically limit RMM studies to the evaluation of only a limited number of regimens 98 in a given study. Moreover, the analysis of regimen performance within a given study has 99 historically utilized conventional group-to-group statistical comparisons designed to evaluate the 100 proportion of mice relapsing at a relatively small number of treatment durations (e.g., three to 101 five). Lenaerts, et al., have demonstrated that the RMM requires at least 15 animals per regimen 102 to detect a 50% reduction in relapse probability at a given treatment duration with at least 80% 103 power (14) . This analysis strategy based upon point-by-point comparison of relapsing proportions 104 limits the utility of the model as the differences between candidate regimens are often much 105 smaller. Further, the focus on comparative efficacy at pre-specified treatment durations requires 106 careful selection of multiple treatment durations (and larger numbers of mice) to be tested to ensure 107 identification of regimens that achieve significant rates of cure (e.g., 10% or lower probability of 108 relapse) with a shorter treatment duration than the current standard of care regimen.

To improve the overall utility of RMM study data and interpretation for regimen prioritization, 110 the CPTR Initiative applied modeling and simulation-based techniques to the analysis of RMM 111 6 study data across multiple pooled, historical datasets. The objective of this work, which was based 112 on data from a total of 28 studies conducted in two separate laboratories, was to develop a suitable 113 model-based regression approach to: 1) determine the treatment duration-dependent relapse 114 probability profiles for the included drug regimens, 2) quantify the magnitude of inter-study 115 variability in treatment response and assess the impact of study-level covariates on treatment 116 response, and 3) calculate key metrics of interest, namely treatment duration required to reach 50% 117 and 10% relapse probability (T50 and T10, respectively), for comparison of relative regimen 118 performance in the RMM when adjusted for study-level covariates. By applying a model-based 119 analysis, it was expected that inter-study differences could be accounted for and unbiased estimates 120 of informative parameters, such as T10, could be reported to support decision-making. Importantly, 121 the model-based approach was also expected to yield uncertainty in parameters, such as T10, which 122 will be a function of the amount of and consistency in available data, further contributing to 123 informed decision-making. Model-based analysis was performed using a nonlinear mixed-effects modeling approach. Metrics of interest, namely T10 and T50, were calculated as follows from the model estimates Table 1 , with a further summary of data for each 234 regimen provided in Table 2 . objective of extracting treatment duration-dependent relapse probability profiles from the model 263 to assess differences in response between regimens, and resulted in further model improvements.

In the second stage of the analysis, the model was updated to support the inclusion of additional 

272

Estimates for the treatment-specific fixed-effects parameters are presented in Table 4 , whereas To assess predictive capability of the final model, a VPC was performed with stratification by 276 treatment (Fig. 2) and BASE as well as by study (Fig. S-3 Table 5 along 289 with regimen rank order based on the median values. As seen in Fig. 3 The ability to account for study-level covariates and quantify inter-study variability highlights 351 a further advantage to the model-based meta-analysis methodology applied herein, in that unbiased 352 regimen-specific parameters were estimated simultaneously across data from all studies.

Specifically, the treatment regimen fixed-effects parameters correspond to the covariate-354 normalized relapse probability versus treatment duration profiles after adjustment for residual 355 inter-study variability. This is significant in that it allows for robust "apples-to-apples" covariates that may not be known at this time, must be considered for cross-study comparisons. In 360 this regard it is noted that the ability to make cross-study comparisons within this meta-analysis 361 were bolstered by the presence of reference regimens (e.g., HRZ/HR), which helped to partition 362 inter-study variability from treatment effects, especially for those regimens for which data were 363 available from only a single study or where the number of treatment durations was limited. In the 364 latter case, even with a reference regimen "anchor," model stability often necessitated grouping 365 similar regimens together to share an identical fixed-effect term for either INT or SLP. Groupings 366 are indicated in Table 4 , although it is noteworthy that multiple regimens did not share the same 367 18 fixed effects for both parameters except for HRE and HRE/HR as well as HRZE and HRZE/HRZ.

Hence, aside from these regimens which are treated as identical (which is reasonable based upon 369 their similarity, being differentiated only on the presence and absence of ethambutol beyond two 370 months treatment duration), the structure of the final model enabled the calculation of regimen-371 specific relapse probability versus treatment duration profiles.

With regard to relative regimen efficacy, the results in Fig. 3, Fig. 4 , and Table 5 illustrate that, 

WHO global progress report on tuberculosis elimination

Latent TB Infection: Updated and consolidated 444 guidelines for programmatic management

World Health Organization, Global Tuberculosis Programme

Committee for Medicinal Products for 449 Human Use. Summary of Opinion: Deltyba

Pretomanid product insert. Silver Spring (MD)

Sirturo (bedaquiline) product insert

USPHS Tuberculosis Short-Course 457

Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final 458 results

Critical path to TB drug regimens

A patient-level pooled analysis of 463 treatment-shortening regimens for drug-susceptible pulmonary tuberculosis

Nonclinical models 467 for antituberculosis drug development: a landscape analysis

Comprehensive analysis of 471 methods used for the evaluation of compounds against Mycobacterium tuberculosis

Importance of confirming in vivo efficacy data of novel antibacterial drug regimens 476 against various strains of Mycobacterium tuberculosis

Comparative studies evaluating mouse models used 480 for efficacy testing of experimental drugs against M. tuberculosis

Statistical limitations to the Cornell model of 483 latent tuberculosis infection for the study of relapse rates

Evaluation of moxifloxacin-containing regimens in pathologically distinct murine 487 tuberculosis models

Treatment-shortening effect of a novel regimen combining 490 clofazimine and high-dose rifapentine in pathologically distinct mouse models of 491 tuberculosis

Impact of clofazimine dosing on treatment shortening of the first-line regimen in a mouse 497 model of tuberculosis

Clofazimine shortens the duration of the first-line treatment 501 regimen for experimental chemotherapy of tuberculosis

Daily dosing of rifapentine cures 505 tuberculosis in three months or less in the murine model

Sterilizing activity of pyrazinamide 508 in combination with first-line drugs in a C3HeB/FeJ mouse model of tuberculosis

Sterilizing activity of novel TMC207-and PA-824-containing 512 regimens in a murine model of tuberculosis

Powerful bactericidal and sterilizing activity of a regimen containing PA-824

moxifloxacin, and pyrazinamide in a murine model of tuberculosis

Contribution of oxazolidinones 520 to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse 521 model of tuberculosis